Member Info for Yorkshirepragma

Potential for which is a share of market of....
https://www.prnewswire.com/news-releases/the-global-autoimmune-disease-therapeutics-market-size-is-expected-to-reach-149-4-billion-by-2025--rising-at-a-market-growth-of-4-34-cagr-during-the-forecast-period-300902336.html
Together with other JVs etc..
Sound.

https://uk.finance.yahoo.com/news/adeptrix-closes-series-financing-commercialize-211600322.html?guccounter=1&guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvLnVrLw&guce_referrer_sig=AQAAANd9BPhCaq4PC-URZHaZufwpdpEZqExtKembiq4TX5QswkXDme_QmCgKbg52w7u44y2PIGN680QxoSMWE0lwTKYWHgMVEUNvZtiaJ96IqXTaUayS8K4wTRqOQnIxB8eCdRwd1pfL1Hx4Kz2DM9-PZdldr4m56caF47O2V9SXRO29

O2, : in the Pharms/ Medtech game ,beaurocracy and defined acceptance product process rule.
Fascinatingly today (Mr Myles McNulty @ Twitter) spotted the name ascribed to the LFT
Giving a designation means alot...I’d give it no more than 10 days max before clarification ,hopefully less.
GLA

Now that’s a real piece of news....well spotted.

Energy shares..
.price correction...
https://www.bibonline.co.uk/products/healgen-covid-19-rapid-antigen-test-kit-box-of-20-tests

Once Again..Supporting mention of Lateral Flow tests and value of taking such tests to find asymtomatic carriers.
GLA

Point of order: BJ comment reflects the position that the ‘ manufacturers /developers/component teams’ will now be working in ‘sharing mode’. This takes place in several critical industry sectors’ ‘as and when’. Take this as read.

U.K. a fraction of total.
WHO commentary inset on using <5% ‘found’ as an under control signal.(#see text)
Enormous... requirement/demand/ market etc.
Desperately needed , a good LFT will make a mark.
Best wishes to AS étal and the now inter company team who are aiming to deliver.
https://ourworldindata.org/coronavirus-testing

....We’ ve created a U.K. LFT industry....... am sure others heard it in response to are we better off for future pandemics....

Significant anti viral effects, as reported in the Glasgow study .
Investor needed

Government ‘PR’ to present a better test and trace process seems to be upping a gear with the Dido Harding CBI commentary etc..
CBI briefs often head up the momentum.
If there’s no news on the ‘consortiums’ LFT production in next short time period to back this up then , it’ll be disappointing...but unlikely?

GLA

Significant number of antibody(Abcam) reagents can be ‘crossed’ to Affimer applications .
https://www.sciencedirect.com/science/article/pii/S1046592820301182
Story unfolds...
GLA

Abcam...gla

Hardman...apologies

Hartman Commentary , Avacta next Abram? ( P/E 277). ...GLA

02 ,spot on.
Formula will be
Unit Return (x) ; production per annum (y) ; Then,
M.Cap = X x Y x 5-30 .. excluding values attributable to ‘other’ Avacta components.
GLA

And it’s not an easy test,some sig.trips.....any simplification will be a plus if Avacta can come through..
As am sure it will
GLA and the Avacta team too...

https://www.england.nhs.uk/coronavirus/wp-content/uploads/sites/52/2020/11/LFD_NHSStaff_A4_161120_.pdf

2020 Abcam , revenue £260m /adjusted operating profit £44m
2021 Avacta ....??

Parma sub ingenti.....the little are under the great....

https://www.grandviewresearch.com/industry-analysis/covid-19-diagnostics-market

$84bn
@5% take....
GLA